Perthera

Executive Summary

Perthera, Inc. is a U.S.-based healthcare AI company founded in 2013, specializing in precision oncology. Its core product, the Perthera Precision Oncology Platform, leverages artificial intelligence to integrate multi-omic and clinical data, generating personalized, ranked therapy recommendations for cancer patients. By supporting clinical decision-making and accelerating therapeutic innovation, the company aims to establish precision oncology as the standard of care. Despite operating in a competitive landscape, Perthera's AI-driven approach offers the potential to improve patient outcomes and streamline drug development. The company is privately held with no disclosed funding or valuation, but its focus on a high-need area and growing adoption of AI in healthcare position it for strategic partnerships. Near-term catalysts could include collaborations with pharmaceutical firms for clinical trial matching or biomarker discovery, as well as regulatory clearances that validate its platform's clinical utility.

Upcoming Catalysts (preview)

• Q1 2026Pharmaceutical Partnership for Clinical Trial Matching70% success
• Q3 2026FDA Clearance for a Specific Tumor Type Indication40% success
• TBDSeries A Funding Round Announcement50% success